The U.S. Supreme Court has agreed to hear arguments in a "pay-for-delay" case that has the Federal Trade Commission accusing generic drugmakers of violating competition laws by agreeing to accept $42 million in annual payments in exchange for not selling generic versions of a more-expensive brand-name testosterone gel.
Supreme Court slates 'pay-for-delay' case
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.